A Study on Budesonide/ Formoterol vs. Fluticasone/ Salmeterol Inhaled Combination in Moderate to Severe Asthma
Journal Title: Journal of Pharmaceutical and Biomedical Sciences - Year 2014, Vol 6, Issue 2
Abstract
Background and Objectives The addition of an inhaled long-acting β2-agonist (LABA) to an inhaled corticosteroid (ICS) gives optimal control of asthma in most patients. The LABA salmeterol xinafoate (salmeterol) with inhaled corticosteroid (ICS) fluticasone propionate (fluticasone) and formoterol with budesonide are available as a combination product pMDI in a single aerosol inhaler. This study compared the efficacy and safety of commercially available salmeterol/fluticasone with formeterol/budesonide. Materials and Methods Patients aged >12 years inclusive of either sex (N = 40) with persistent asthma as defined by NHLBI for >6 months prior to screening were included in the study. After a screening phase (1 week), eligible patients were enrolled in the study with 2 weeks run-in period. Eligible patients were randomized to receive either of the two treatment groups [HFA-propelled pMDI salmeterol/fluticasone (50/100 mcg) or HFApropelled formoterol/budesonide (6/100 mcg) pMDI] in a ratio of 1:1 for the 12-week treatment period. The primary objective was to demonstrate non-inferiority of salmeterol/ fluticasone vs. formoterol/budesonide, measured by mean pre-dose forced expiratory volume in the first second (FEV1), at week 12. Results This study provides evidence for the primary efficacy endpoint that salmeterol/ fluticasone was statistically as well as clinically non-inferior to formoterol/budesonide in the treatment of patients with persistent asthma. This was supported by secondary endpoints which demonstrate that salmeterol/fluticasone appeared to be comparable to formoterol/budesonide in terms of efficacy for the secondary efficacy endpoints (morning PEFR, evening PEFR, diurnal variability of PEFR, daytime and night-time asthma symptoms score, average need for short-acting β2-agonists, proportion of patients that required rescue medication, patients with nocturnal asthma, patients without asthma symptoms of score 0 and average number of days without asthma symptoms of score 0). Salmeterol/fluticasone was safe and well tolerated; and safety profile is comparable to comparator formoterol/budesonide. Conclusion The results of this study demonstrate that HFA formulations of salmeterol/ fluticasone and formoterol/budesonide are clinically interchangeable. Overall, the study indicates that HFA-propelled salmeterol/fluticasone (50/100 mcg) pMDI was safe, well tolerated and non-inferior in efficacy compared to HFA-propelled formoterol/budesonide (6/100 mcg) pMDI.
Authors and Affiliations
Sarat Kumar Behera
Keywords
Related Articles
- EP ID EP183981
- DOI -
- Views 136
- Downloads 0
Improving Soluble Expression of Curcin-Transferrin Receptor-binding Peptide Fusion Protein with Glutathione Transferase-Small Ubiquitin-related Modifier System
Curcin can inhibit the proliferation of tumor cells and facilitate tumor cell apoptosis. In the current study, transferrin receptor (TFR)-binding peptide, TfRBP9, was fused with curcin and significantly enhanced the targ...
Review on Pressure Sores
Pressure sore is a localised injury to the skin and underlying tissue caused due to unrelieved pressure on pressure points or bony prominences. The predisposing factors causing pressure ulcers are both intrinsic and extr...
Inguinal sarcoidosis– an Unusual Presentation
Sarcoidosis is a chronic multisystemic disorder of unkown etiology. It is characterised by non caseating granulomas with pulmonary involvement, bilateral, in 90% cases. Hilar or paratracheal pulmonary lymphnodes are ofte...
Identification of Strain H41-55 and Chemical Constituents from its Fermentation Broth
The strain H41-55 was identified as Streptomyces antibioticus according to morphological, cultural, and physiological and biochemical characteristics in combination with 16S rDNA sequence and phylogenetic tree analysis o...
Efficacy and Tolerability of Fixed Dose Combination Valsartan/Amlodipine to Achieve Blood Pressure Target in Iraqi Hypertensive Patients
Background Fixed dose combinations (FDCs) are one of the options for improving blood pressure (BP) goal attainment. However, it has not been studied previously in Iraqi patients. Objective The aim of the study is to eval...